Brent Saunders is a proven leader with more than 25 years of experience across the health care sector. He has served in senior executive roles at several global pharmaceutical and health care companies, where he has successfully overseen numerous value-enhancing initiatives, transactions and integrations.
He rejoined Bausch + Lomb as Chief Executive Officer and Chairman of the Board of Directors in March 2023. Mr. Saunders initially served as CEO from 2010 until 2013, when the company was acquired by Bausch Health Companies Inc. (then known as Valeant Pharmaceuticals, Inc.).
Mr. Saunders previously co-founded and served as Chairman of the Board of Vesper Healthcare Acquisitions Corp. Prior to that, he was Chairman, President and CEO of Allergan plc. until the company’s $63 billion acquisition by AbbVie Inc in 2020. Before that, he was President and CEO and a director of Forest Laboratories Inc., until that company’s $25 billion merger with Actavis plc. in 2014, when he was named CEO of the combined business. He then successfully led Actavis’ $66 billion acquisition of Allergan.
Mr. Saunders’ first role as an executive officer in the pharmaceuticals and health care space was as a member of the executive management team at Schering-Plough Corporation. While there, he led the integration of Organon Biosciences N.V., after Organon was acquired by Schering-Plough, as well as the merger between Schering-Plough and Merck & Co., Inc.
Earlier in his career, Mr. Saunders was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care, Inc., Senior Vice President of Compliance, Legal and Regulatory at Home Care Corporation of America, and Chief Compliance Officer for the Thomas Jefferson University Health System.
Mr. Saunders currently serves as Chairman of the Board of The Beauty Health Company (Nasdaq: SKIN) and as a director of ARS Pharmaceuticals, Inc. (Nasdaq: SPRY). He is Chairman of the Board of Roam, a director of Cambrian BioPharma and Arena AI, and a Nextech board advisor. His prior board experience includes BridgeBio Pharma, Inc. (Nasdaq: BBIO), Cisco Systems, Inc. (Nasdaq: CSCO), Glo Pharma, OcuTerra Therapeutics and Osmind. He is also a member of the Executive Committee of Mt. Sinai Medical Center.
Mr. Saunders holds a B.A. from the University of Pittsburgh, a J.D. from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
What is Brent L. Saunders' net worth?
The estimated net worth of Brent L. Saunders is at least $106.59 million as of August 12th, 2024. Mr. Saunders owns 5,921,769 shares of Bausch + Lomb stock worth more than $106,591,842 as of December 22nd. This net worth approximation does not reflect any other assets that Mr. Saunders may own. Learn More about Brent L. Saunders' net worth.
How old is Brent L. Saunders?
Mr. Saunders is currently 54 years old. There are 6 older executives and no younger executives at Bausch + Lomb. The oldest executive at Bausch + Lomb is Mr. Alan Waterhouse CPFA, MBA, Executive VP and Chief Supply Chain & Operations Officer, who is 64 years old. Learn More on Brent L. Saunders' age.
How do I contact Brent L. Saunders?
Has Brent L. Saunders been buying or selling shares of Bausch + Lomb?
Brent L. Saunders has not been actively trading shares of Bausch + Lomb in the last ninety days. Most recently, on Monday, August 5th, Brent L. Saunders bought 32,250 shares of Bausch + Lomb stock. The stock was acquired at an average cost of $15.66 per share, with a total value of $505,035.00. Following the completion of the transaction, the chief executive officer now directly owns 595,169 shares of the company's stock, valued at $9,320,346.54. Learn More on Brent L. Saunders' trading history.
Are insiders buying or selling shares of Bausch + Lomb?
In the last twelve months, Bausch + Lomb insiders bought shares 1 times. They purchased a total of 32,250 shares worth more than $505,035.00. The most recent insider tranaction occured on August, 5th when CEO Brent L Saunders bought 32,250 shares worth more than $505,035.00. Insiders at Bausch + Lomb own 0.2% of the company.
Learn More about insider trades at Bausch + Lomb. Information on this page was last updated on 8/5/2024.
